Use of persistent infections with vaccinia virus recombinants to introduce alterations in foreign proteins: an application to HIV-1 env protein

Virus Res. 1996 Dec;46(1-2):45-56. doi: 10.1016/s0168-1702(96)01380-9.

Abstract

With the aim of generating a virus-cell system to introduce alterations in proteins of interest--which may be of use in studies of their biological functions--we established a persistent infection on a B-lymphoma cell line (A20.2J) with vaccinia virus (VV) recombinants. As a model, we used a vaccinia virus recombinant expressing the human immunodeficiency virus HIV-1 env gene. In this unique virus-cell system, we found that it is possible to introduce several structural and functional alterations in the env protein with passage numbers. From passage 10-20, two new env products emerged: an uncleaved gp160 and a glycoprotein fragment of 110 kDa. The uncleaved gp160 exhibit interesting properties as an immunogen. This protein forms stable oligomers, is not released from the cells, cannot fuse CD4+ presenting HeLa cells and activates a stronger cellular immune response than the parental cleaved env. In contrast, the 110 kDa product is a poor immunogen, since it lacks the gp41 domain, cannot form oligomers, accumulates intracellularly and cannot fuse CD4+ cells. In the persistently infected cells we have also found alterations in another heterologous protein-beta-galactosidase-a gene inserted in the same locus of VV as the env gene. This alteration resulted in a truncation of the (beta-galactosidase protein from 125 kDa to about 70 kDa. A similar size truncation of env and of beta-galactosidase was observed in many of the isolated VV recombinants.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Antibodies, Viral / biosynthesis
  • Gene Expression Regulation, Viral / immunology
  • Gene Products, env / chemistry
  • Gene Products, env / genetics*
  • HIV-1 / chemistry
  • HIV-1 / genetics*
  • Humans
  • Lymphocyte Activation
  • Lymphoma, B-Cell / genetics
  • Lymphoma, B-Cell / virology
  • Mice
  • Recombination, Genetic*
  • Serial Passage
  • Tumor Cells, Cultured
  • Vaccinia / genetics*
  • Vaccinia / metabolism
  • Vaccinia virus / genetics*
  • Vaccinia virus / immunology
  • Vaccinia virus / metabolism

Substances

  • Antibodies, Viral
  • Gene Products, env